SCYNEXIS (SCYX) Receives a Buy from Brookline Capital Markets

By Ryan Adsit

In a report released yesterday, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on SCYNEXIS (SCYXResearch Report), with a price target of $10. The company’s shares closed yesterday at $1.76.

According to, Raja is a 4-star analyst with an average return of 19.3% and a 58.0% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Acer Therapeutics Inc, and Heat Biologics.

SCYNEXIS has an analyst consensus of Strong Buy, with a price target consensus of $5.88, representing a 234.1% upside. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $5 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.15 and a one-year low of $0.35. Currently, SCYNEXIS has an average volume of 1.38M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.